Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 25, 2014

Primary Completion Date

November 21, 2017

Study Completion Date

December 11, 2017

Conditions
Myocardial Infarction (MI)
Interventions
BIOLOGICAL

Revelise (GENERIUM, Russia)

"1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg.~ \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes.~2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg.~ * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg."

BIOLOGICAL

Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)

"1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg.~ \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes.~2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg.~ * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg."

Trial Locations (22)

101000

"SBHI State Budgetary Healthcare Institution of MHD", Moscow

111539

"Moscow City State Budgetary Healthcare Institution Filatov City Clinical Hospital No. 15 of Moscow Healthcare Department", Moscow

117292

"State Budgetary Healthcare Institution of the city of Moscow City Clinical Hospital No. 64 of Moscow Healthcare Department", Moscow

117997

"Federally Funded Higher Education Institution Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation", Moscow

125284

"Moscow City State Budgetary Healthcare Institution Botkin City Clinical Hospital of Moscow Healthcare Department", Moscow

127644

"SBHI CCH No. 81 MHD", Moscow

129090

"SBHI Sklifosovsky Research Institute of Emergency Medicine of MHD", Moscow

163001

"City Budgetary Healthcare Institution of Arkhangelsk Region First City Clinical Hospital named after E.E. Volosevich", Arkhangelsk

192242

"SI St. Petersburg Dzhanelidze Research Institute of Emergency Medicine", Saint Petersburg

199106

"St. Petersburg State Budgetary Healthcare Institution Pokrovskaya City Hospital", Saint Petersburg

344068

"Municipal Budgetary Healthcare Institution City Emergency Medical Hospital of Rostov-on-Don", Rostov-on-Don

355000

"SBHI SC Stavropol Regional Clinical Hospital", Stavropol

410028

FSI Saratov Research Institute of Cardiology of Russian medical Technologies, Saratov

410039

"State Healthcare Institution City Clinical Hospital No. 12", Saratov

430005

"FSBEI of HVE Mordovia State University named after N.P. Ogarev, Medical Institute, SBHI MR City Clinical Hospital No. 3", Saransk

450106

SBHI Republican Cardiology Center, Ufa

614107

Municipal Health Care Institution City Clinical Hospital No.4, Perm

630047

"Novosibirsk Region State Budgetary Healthcare Institution City Clinical Hospital No. 1", Novosibirsk

630051

"State Budgetary Healthcare Institution of Novosibirsk City Clinical Hospital No. 2", Novosibirsk

630054

"Novosibirsk Region State Budgetary Healthcare Institution City Clinical Hospital No. 34", Novosibirsk

650002

"Federal State Budgetary Scientific Institution Scientific Research Institute for Complex Issues of Cardiovascular Diseases", Kemerovo

656055

"Regional State Budgetary Healthcare Institution Altai Regional Cardiological Dispensary", Barnaul

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY

NCT07146360 - Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction | Biotech Hunter | Biotech Hunter